(A) Relative expression of complement-related transcripts taken from microarray analysis performed on hippocampus from 5mo REV-ERBα KO (RKO) and littermate WT mice (N = 3/genotype), global BMAL1 KO mice (BKO, N = 2), or 12mo Nestin-Cre;Bmal1f/f mice (NCre+), and littermate Cre- controls (NCre-, N = 3/group). Colors indicate fold change versus control. (B) qPCR analysis of 11 month old control (Cre-) and neuron-specific Bmal1 KO mice (Camk2a-iCre+;Bmal1fl/fl) for complement genes (N = 3–4/group). (C) qPCR analysis of control (Cre-) and astrocyte-specific Bmal1 KO mice (Aldh1l1-CreERT2+;Bmal1fl/fl) for complement genes (N = 5 mice/group). (D) qPCR analysis of control (Cre-) and microglia-specific Bmal1 KO mice (Cx3cr1- CreERT2+;Bmal1fl/fl) for complement genes (N = 4–8/group). For C and D, all mice (Cre- or +) were treated with tamoxifen at 2mo and harvested at 4mo, mixed sexes, Cre- littermates were used as controls. (E) qPCR analysis of mRNA from primary cortical neurons isolated from Bmal1fl/fl mice, treated with AAV8-GFP (control) or AAV8-Cre (n = 4–5 wells/group). (F) qPCR analysis of WT or RKO mouse hippocampal tissue for complement genes (N = 5–10 mice/group). (G) Representative 40X maximum intensity projections of GFAP and C3 staining as well as the merged channel in the hippocampus of 5mo WT or RKO mice and the associated normalized volumes for C3-GFAP staining (n = 8 mice, N = 4/group). (H) Representative 40X maximum intensity projections of Iba1 and C3 staining as well as the merged channel in the hippocampus of 5mo WT or RKO mice. Scale bar = 100 µm. *p<0.05 **p<0.01 ***p<0.001, ns = not significant, by two-tailed T-test with Welch’s correction.